Published in STAT, a thought-provoking piece from Children's Tumor Foundation President Annette Bakker on the critical need to distinguish between “repurposing” FDA-approved drugs for new indications vs “repositioning” non-FDA approved shelved assets for emerging indications. The terms are often used interchangeably, but clarifying the distinction will help accelerate the development of cures not just for NF (neurofibromatosis and schwannomatosis), but for all rare diseases that collectively affect over 30 million Americans.
Read the piece here: https://www.statnews.com/2023/06/27/drug-repurposing-repositioning-rare-diseases/
